Original Research

Published on 15 Oct 2024

Exploring global perspectives on the use of computer-based simulation in pharmacy education: a survey of students and educators

in ELSI in Science and Genetics

Ahmed M. Gharib
Ivan K. Bindoff
Gregory M. Peterson
Mohammed S. Salahudeen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1494569

385 views

Policy and Practice Reviews

Published on 27 Aug 2024

The anatomy of a data transfer agreement for health research

in ELSI in Science and Genetics

Lee Swales
Amy Gooden
Donrich Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1332700

597 views

Hypothesis and Theory

Published on 17 Jun 2024

Open optimism as an “embodied-health” ethic for the information era

in ELSI in Science and Genetics

Meshandren Naidoo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1331237

823 views

Original Research

Published on 10 May 2024

Do biobanks need pharmacists? Support of pharmacy students to biobanking of human biological material for pharmaceutical research and development

in ELSI in Science and Genetics

Jan Domaradzki
Anita Majchrowska
Judyta Cielecka-Piontek
Dariusz Walkowiak

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1406866

1,144 views

Correction

Published on 14 Mar 2024

Corrigendum: Liability for harm caused by AI in healthcare: an overview of the core legal concepts

in ELSI in Science and Genetics

Dane Bottomley
Donrich Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1366004

850 views
1 citation

Policy and Practice Reviews

Published on 12 Mar 2024

Forcing a square into a circle: why South Africa’s draft revised material transfer agreement is not fit for purpose

in ELSI in Science and Genetics

Paul Esselaar
Lee Swales
Devarasi Bellengère
Banele Mhlongo
Donrich Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1333672

1,138 views

Review

Published on 01 Mar 2024

A pathway to strengthening open science: comments on the draft South African Ethics in Health Research Guidelines

in ELSI in Science and Genetics

Amy Gooden

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1304950

1,563 views

Original Research

Published on 20 Feb 2024

Patients’ knowledge, preferences, and perspectives about data protection and data control: an exploratory survey

in ELSI in Science and Genetics

Teodora Lalova-Spinks
Robbe Saesen
Mitchell Silva
Jan Geissler
Iryna Shakhnenko
Jennifer Catherine Camaradou
Isabelle Huys

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1280173

5,003 views
1 citation

Review

Published on 14 Dec 2023

Liability for harm caused by AI in healthcare: an overview of the core legal concepts

in ELSI in Science and Genetics

Dane Bottomley
Donrich Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1297353

4,975 views
6 citations

Perspective

Published on 23 Nov 2023

Does data protection law in South Africa apply to pseudonymised data?

in ELSI in Science and Genetics

Donrich Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1238749

1,791 views
2 citations

Perspective

Published on 28 Aug 2023

Analysis of ethics dumping and proposed solutions in the field of biomedical research in China

in ELSI in Science and Genetics

Bohua Liao
Yonghui Ma
Ruipeng Lei

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1214590

2,682 views
3 citations

Systematic Review

Published on 24 Aug 2023

Mapping the regulatory landscape of AI in healthcare in Africa

in ELSI in Science and Genetics

Beverley Alice Townsend
Irvine Sihlahla
Meshandren Naidoo
Shiniel Naidoo
Dusty-Lee Donnelly
Donrich Willem Thaldar

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1214422

10,347 views
13 citations

Editorial

Published on 12 Jun 2023

Editorial: Opportunities and challenges in reusing public genomics data

in ELSI in Science and Genetics

Mahmoud Ahmed
Deok Ryong Kim

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1226756

1,993 views

Review

Published on 07 Apr 2023

The evolving culture of medical cannabis in Canada for the management of chronic pain

in ELSI in Science and Genetics

H. Clarke
M. Fitzcharles

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1153584

10,444 views
9 citations

Review

Published on 26 Oct 2022

Fabry disease: Mechanism and therapeutics strategies

in ELSI in Science and Genetics

Xi Li
Xiangyi Ren
Yabing Zhang
Lin Ding
Minfeng Huo
Qian Li

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1025740

12,248 views
22 citations

Original Research

Published on 01 Jun 2022

CLP1 is a Prognosis-Related Biomarker and Correlates With Immune Infiltrates in Rheumatoid Arthritis

in ELSI in Science and Genetics

Zhenyu Zhao
Shaojie He
Sheng Tang
Xiaofeng Lai
Jie Ren
XinCheng Yu
Jinhua Lin
Mohan Wang
Mariya M. El Akkawi
Shan Zeng

Frontiers in Pharmacology

doi 10.3389/fphar.2022.827215

6,903 views
5 citations

Navigation group

Articles

Exploring global perspectives on the use of computer-based simulation in pharmacy education: a survey of students and educators

The anatomy of a data transfer agreement for health research

Open optimism as an “embodied-health” ethic for the information era

Do biobanks need pharmacists? Support of pharmacy students to biobanking of human biological material for pharmaceutical research and development

Corrigendum: Liability for harm caused by AI in healthcare: an overview of the core legal concepts

Forcing a square into a circle: why South Africa’s draft revised material transfer agreement is not fit for purpose

A pathway to strengthening open science: comments on the draft South African Ethics in Health Research Guidelines

Patients’ knowledge, preferences, and perspectives about data protection and data control: an exploratory survey

Liability for harm caused by AI in healthcare: an overview of the core legal concepts

Does data protection law in South Africa apply to pseudonymised data?

Analysis of ethics dumping and proposed solutions in the field of biomedical research in China

Mapping the regulatory landscape of AI in healthcare in Africa

Editorial: Opportunities and challenges in reusing public genomics data

The evolving culture of medical cannabis in Canada for the management of chronic pain

Fabry disease: Mechanism and therapeutics strategies

CLP1 is a Prognosis-Related Biomarker and Correlates With Immune Infiltrates in Rheumatoid Arthritis